Compass Pathways stock rating reiterated at Buy by BTIG
BTIG reiterated a Buy rating and $25 price target for Compass Pathways (CMPS), citing completed trials and upcoming FDA action. The stock trades at $9.11, down 29% in a week. InvestingPro notes undervaluation, with analyst targets up to $65. The company reported a smaller-than-expected Q3 loss, $0.31 per share vs. $0.36 estimate.
How this was made
The 30-second read
Why it matters
The analyst upgrade reflects confidence in trial data and a narrower Q3 loss, suggesting near‑term buying interest.
Market read
The new rating and price target could trigger short‑term price appreciation for CMPS, while signaling optimism for the broader psychedelic sector.
What to watch
Potential delays in DEA rescheduling and reimbursement coding could dampen upside.
Background
Compass Pathways (CMPS) is developing COMP360, a psilocybin‑based treatment for treatment‑resistant depression, with pending FDA and DEA actions.
Ticker impact
BTIG reiterated a Buy rating and raised the price target to $25, citing recent trial data and a smaller-than-expected Q3 loss.
likely upward pressure as investors price in the new target and trial progress
The rating change is a fresh, primary disclosure and includes a concrete price target, which typically moves the stock in the short term.
Market effects
Positive signal for the biotech/psychedelic therapy sector as a major player receives an upgraded rating.
Limited to U.S. biotech investors; no broader regional effect.
Minor, confined to investors tracking psychedelic drug developments.
Counterpoint
The rating may be premature given regulatory uncertainties and the need for FDA approval.
Key entities
- companyCompass Pathways
Biotech firm developing psilocybin therapy.
- analystBTIG
Equity research firm issuing the Buy rating.
